Our attorneys advised longtime client Pfizer Inc. in its acquisition of Bamboo Therapeutics, Inc., a privately held biotechnology company. Our attorneys previously represented Pfizer in its acquisition of approximately 22 percent of Bamboo’s fully diluted equity for a payment of approximately $43 million during the first quarter of 2016. Under the terms of the current transaction, Pfizer acquired all of the remaining equity of Bamboo for an upfront cash payment of $150 million, with up to $495 million of contingent milestone payments.

Email Disclaimer